Blood Review Time

For year-over-year citation data, see the Blood citation metrics page.

Blood was up from 20.3 in 2023 to 23.1 in 2024 after the post-pandemic hematology normalization period. The practical takeaway is that the journal still holds a strong structural baseline as the field's main flagship rather than merely riding a temporary citation wave.

Three factors make Blood's timeline more predictable:

Lower desk rejection rate. At ~40-50%, Blood sends more papers to review than Nature (~80% desk rejection) or Cell (~70-80%). This means more papers get a chance at peer review, and the editorial triage is less of a bottleneck.

Well-defined reviewer community. Hematology is a specific specialty with a identifiable reviewer pool. The ASH membership directory gives editors a clear map of who reviews what. Reviewer recruitment that takes 3-4 weeks at interdisciplinary journals often takes 1-2 weeks at Blood (per current SciRev data and the journal's publisher portal).

Broad scope within one specialty. Blood publishes basic, clinical, and translational hematology. This means papers rarely get desk-rejected for "scope mismatch" the way they do at journals with narrower editorial identities. If the paper is hematology, the scope question is usually settled.

Blood editors specifically screen whether the manuscript changes practice or understanding across hematology rather than within one narrow malignant, coagulation, or immunology slice. That is the real difference between a smooth flagship review and a redirect conversation.

Blood reviewers evaluate the paper within the standards of their hematology subspecialty. The review criteria shift by paper type:

For basic hematology: Is the mechanism novel? Are the model systems appropriate? Does the finding advance understanding of blood cell biology or blood disease?

For clinical hematology: Is the evidence strong enough to inform treatment? Are the endpoints clinically meaningful? Is the patient population representative?

For translational work: Does the bench-to-bedside bridge hold? Is the human relevance supported by data, not just discussion?

Blood reviewers tend to be constructive. The ASH culture emphasizes improving papers rather than gatekeeping. Revision requests are usually reasonable and focused.

When Blood editors see hematology merit but the paper isn't quite at the flagship threshold, they offer a redirect to Blood Advances (IF ~7). This is the most common alternative outcome after desk rejection.

The redirect includes the editor's assessment and sometimes the initial reviewer comments. This speeds up the process at Blood Advances significantly. Many papers that end up in Blood Advances went through this route.

Taking the redirect is usually the right call. Blood Advances shares the ASH brand, the same reviewer community, and reaches the same hematology audience.

SciRev data for Blood are sparse, but the small current set points to immediate decisions measured in days and first review rounds around four weeks. That is directionally consistent with Blood's reputation for quick specialty-specific handling once the paper is clearly in range.

Blood's timeline only helps if it changes what you do next. In practice, the useful question is whether the manuscript is strong enough for the flagship ASH route or whether the same hematology audience would be reached faster through a different journal in the cluster. The timing profile matters because Blood is not slow in a generic way. It is usually slow for papers that trigger real disease-model, mechanism, or clinical-translation scrutiny.

That is why authors should read the week count together with the journal-choice question. If the paper is clearly hematology-first and broad enough for the main Blood readership, a 6-10 week first-decision window is usually worth tolerating. If the editorial case is thinner, the same timeline may just be delaying an outcome that a more realistic target would have clarified sooner.

• Blood submission guide

• Blood upload workflow

• Blood citation metrics

• Blood selectivity context

• How to avoid desk rejection at Blood

• Is Blood a good journal?

For Blood-targeted manuscripts, three patterns most consistently predict slow review at Blood (American Society of Hematology). In our pre-submission review work on Blood-bound manuscripts, the patterns below are the same ones our reviewers flag. The named editorial-culture quirk: Blood reviewers expect both mechanistic depth and explicit clinical-translation pathway; mechanism-only or clinical-only papers extend revision.

Scope-fit ambiguity in the abstract. Blood editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (hematology research with mechanistic depth and clinical-translation pathway). The named failure pattern: mechanism-only papers without clinical-translation pathway extend revision rounds. Check whether your abstract reads to Blood's scope →

Methods package incomplete for the journal's reviewer pool. Blood reviewers expect specific methodological detail. Clinical observational studies without mechanistic underpinning get desk-rejected within 7-10 days. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Blood (American Society of Hematology) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: ashpublications.org. Manuscript constraints: 250-word abstract limit and 5,000-word main-text cap (Blood enforces during desk-screen).

We reviewed each of these constraints against current journal author guidelines (accessed 2026-05-08); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights pre-submission review signal for Blood (American Society of Hematology). Across our pre-submission reviews of Blood-bound manuscripts, the editorial-culture mismatch we see most consistently is that Blood reviewers expect both mechanistic depth and explicit clinical-translation pathway; mechanism-only or clinical-only papers extend revision.

In our pre-submission review work, Blood-targeted review timelines tend to split between manuscripts that clear Blood's scope-fit threshold quickly and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

How this page was researched: sources used include Blood's ASH author guide, Blood article-type and peer-review guidance, Blood portfolio transfer information, Clarivate JCR 2025 metrics, SciRev author-reported timing, and our pre-submission review work on hematology manuscripts prepared for Blood, Blood Advances, Leukemia, Haematologica, and adjacent oncology or immunology journals. We did not test a private live Blood submission account for this page; status and timing guidance is based on public ASH materials, documented author experience, and pre-submission review patterns.

For separate decisions, use the Blood selectivity context, Blood upload workflow, Blood cover letter guide, or Blood journal overview.

Published Blood review-time medians mask real variation. Desk rejections at Blood (typically completing within the first 1-2 weeks) pull the median down; papers that pass desk-screen and enter full peer review experience longer waits than the median suggests. Seasonal effects matter: December submissions sit longer due to reviewer holiday availability, and September-October sees a backlog from the academic-year start at Blood (American Society of Hematology). The published median does not include acceptance-to-publication production time.

A Blood desk-rejection risk check scores fit against the journal's editorial bar.